|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On February 5, 2015, Aralez Pharmaceuticals Inc. (ARLZ) announced that the planned merger between Pozen, Inc. and Tribute Pharmaceuticals Canada, Inc. was complete following approval by the shareholders of each company. The strategy behind Aralez is that the company will become a cardiovascular focused specialty pharmaceutical company with support from a pain-focused franchise. As a reminder, in conjunction with the completion of the merger, a group of leading healthcare investors, led by Deerfield Management, has committed up to $350 million in capital for Aralez to fund the anticipated commercial launch of YOSPRALA® and for “future acquisitions”.
The hedge fund industry as a whole did not perform particularly well in 2015, but there were a few investment vehicles that managed to greatly outperform the broader market. Steven Cohen’s family office Point72 Asset Management was one of those, as it gained almost 16% last year, while the S&P 500 Index closed the year in negative […]
On December 28, 2015, Pozen, Inc. (POZN) announced that the registration statement on form S-4 filed by Aralez Pharmaceuticals has been declared effective by the Securities and Exchange Commission (SEC) and that the company has set a shareholder meeting for February 2, 2016 to formally vote on the proposed merger with Tribute Pharmaceuticals Canada, Inc. (TBUFF). Tribute will hold a shareholder meeting to vote on the proposed merger on February 1, 2016. The Boards of Directors for both Pozen and Tribute have unanimously recommended the proposed merger, and we anticipate the merger finalizing shortly after the shareholder meetings take place.